Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06191744
Registration number
NCT06191744
Ethics application status
Date submitted
20/12/2023
Date registered
5/01/2024
Date last updated
10/07/2025
Titles & IDs
Public title
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Query!
Scientific title
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Query!
Secondary ID [1]
0
0
2023-506906-38-00
Query!
Secondary ID [2]
0
0
M22-003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EPCORE™FL-2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma (FL)
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Epcoritamab
Treatment: Drugs - Prednisone
Treatment: Drugs - Rituximab
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Vincristine
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Obinutuzumab
Treatment: Drugs - Bendamustine
Experimental: Arm A1: Epcoritamab + Lenalidomide and Rituximab (R2) - Participants will receive epcoritamab in combination with R2 (ER2), followed by epcoritamab during the 120 week treatment duration.
Experimental: Arm A2: Epcoritamab + Lenalidomide and Rituximab (R2) - Participants will receive epcoritamab in combination with R2 (ER2), during the 24 week treatment duration.
Experimental: Arm B: Chemoimmunotherapy (CIT) Option A - Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration.
Experimental: Arm B: Chemoimmunotherapy (CIT) Option B - Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration.
Experimental: Arm C: Lenalidomide and Rituximab (R2) - Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration.
Treatment: Drugs: Epcoritamab
Subcutaneous (SC) Injection
Treatment: Drugs: Prednisone
Oral Tablet
Treatment: Drugs: Rituximab
Intravenous (IV) Infusion
Treatment: Drugs: Lenalidomide
Oral Capsule
Treatment: Drugs: Doxorubicin
IV Injection
Treatment: Drugs: Vincristine
IV Injection
Treatment: Drugs: Cyclophosphamide
IV Injection
Treatment: Drugs: Obinutuzumab
IV Infusion
Treatment: Drugs: Bendamustine
IV Infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)
Query!
Assessment method [1]
0
0
CR30 will be determined by positron emission tomography-computerized tomography (cat scan) \[PET-CT\] per Lugano 2014 criteria, as assessed by independent review committee (IRC).
Query!
Timepoint [1]
0
0
Up to 30 Months
Query!
Primary outcome [2]
0
0
Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS)
Query!
Assessment method [2]
0
0
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Query!
Timepoint [2]
0
0
Up to 10 Years
Query!
Secondary outcome [1]
0
0
Arm A1 vs Arm B: Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time from the date of randomization to the date of death of any cause.
Query!
Timepoint [1]
0
0
Up to 10 Years
Query!
Secondary outcome [2]
0
0
Arm A1 vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate
Query!
Assessment method [2]
0
0
MRD negativity rate, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with follicular lymphoma (FL) MRD at baseline.
Query!
Timepoint [2]
0
0
Up to 10 Years
Query!
Secondary outcome [3]
0
0
Arm A1 vs Arm B: Change from Baseline in Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30)
Query!
Assessment method [3]
0
0
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Query!
Timepoint [3]
0
0
21 Weeks
Query!
Secondary outcome [4]
0
0
Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30
Query!
Assessment method [4]
0
0
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [4]
0
0
Up to 30 Months
Query!
Secondary outcome [5]
0
0
Arm A1 vs Arm C: Percentage of Participants who Achieve CR30
Query!
Assessment method [5]
0
0
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [5]
0
0
Up to 30 Months
Query!
Secondary outcome [6]
0
0
Arm A1 vs Arm A2: Number of Participants with PFS
Query!
Assessment method [6]
0
0
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Query!
Timepoint [6]
0
0
Up to 10 Years
Query!
Secondary outcome [7]
0
0
Arm A1 vs Arm C: Number of Participants with PFS
Query!
Assessment method [7]
0
0
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Query!
Timepoint [7]
0
0
Up to 10 Years
Query!
Secondary outcome [8]
0
0
Arm A1 vs Arm A2: Rate of MRD Negativity
Query!
Assessment method [8]
0
0
MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.
Query!
Timepoint [8]
0
0
Up to 10 Years
Query!
Secondary outcome [9]
0
0
Arm A1 vs Arm C: Rate of MRD Negativity
Query!
Assessment method [9]
0
0
MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.
Query!
Timepoint [9]
0
0
Up to 10 Years
Query!
Secondary outcome [10]
0
0
Arm A1 vs Arm A2: Change from Baseline in PF According to EORTC QLQ-C30
Query!
Assessment method [10]
0
0
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Query!
Timepoint [10]
0
0
Up to 10 Years
Query!
Secondary outcome [11]
0
0
Arm A1 vs Arm C: Change from Baseline in PF According to EORTC QLQ-C30
Query!
Assessment method [11]
0
0
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Query!
Timepoint [11]
0
0
Up to 10 Years
Query!
Secondary outcome [12]
0
0
Arm A1 vs Arm A2: OS
Query!
Assessment method [12]
0
0
OS is defined as the time from the date of randomization to the date of death of any cause.
Query!
Timepoint [12]
0
0
Up to 10 Years
Query!
Secondary outcome [13]
0
0
Arm A1 vs Arm C: OS
Query!
Assessment method [13]
0
0
OS is defined as the time from the date of randomization to the date of death of any cause.
Query!
Timepoint [13]
0
0
Up to 10 Years
Query!
Secondary outcome [14]
0
0
Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30
Query!
Assessment method [14]
0
0
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [14]
0
0
Up to 30 Months
Query!
Secondary outcome [15]
0
0
Arm A1 vs Arm B: Percentage of Participants who Achieve CR30
Query!
Assessment method [15]
0
0
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [15]
0
0
Up to 30 Months
Query!
Secondary outcome [16]
0
0
Arm A1 vs Arm C: Percentage of Participants who Achieve CR30
Query!
Assessment method [16]
0
0
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [16]
0
0
Up to 30 Months
Query!
Secondary outcome [17]
0
0
Arm A1 vs Arm A2: Number of Participants with PFS
Query!
Assessment method [17]
0
0
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Query!
Timepoint [17]
0
0
Up to 10 Years
Query!
Secondary outcome [18]
0
0
Arm A1 vs Arm B: Number of Participants with PFS
Query!
Assessment method [18]
0
0
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Query!
Timepoint [18]
0
0
Up to 10 Years
Query!
Secondary outcome [19]
0
0
Arm A1 vs Arm C: Number of Participants with PFS
Query!
Assessment method [19]
0
0
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Query!
Timepoint [19]
0
0
Up to 10 Years
Query!
Secondary outcome [20]
0
0
Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per IRC
Query!
Assessment method [20]
0
0
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [20]
0
0
Up to 10 Years
Query!
Secondary outcome [21]
0
0
Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per Investigator
Query!
Assessment method [21]
0
0
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [21]
0
0
Up to 10 Years
Query!
Secondary outcome [22]
0
0
Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per IRC
Query!
Assessment method [22]
0
0
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [22]
0
0
Up to 10 Years
Query!
Secondary outcome [23]
0
0
Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per Investigator
Query!
Assessment method [23]
0
0
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [23]
0
0
Up to 10 Years
Query!
Secondary outcome [24]
0
0
Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per IRC
Query!
Assessment method [24]
0
0
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [24]
0
0
Up to 10 Years
Query!
Secondary outcome [25]
0
0
Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per Investigator
Query!
Assessment method [25]
0
0
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [25]
0
0
Up to 10 Years
Query!
Secondary outcome [26]
0
0
Arm A1 vs Arm A2: Number of Participants with Best Overall Response (BOR) per per Investigator
Query!
Assessment method [26]
0
0
BOR is defined as the percentage of participants who achieve CR or partial response (PR) determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Query!
Timepoint [26]
0
0
Up to 10 Years
Query!
Secondary outcome [27]
0
0
Arm A1 vs Arm A2: Number of Participants with BOR per IRC
Query!
Assessment method [27]
0
0
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Query!
Timepoint [27]
0
0
Up to 10 Years
Query!
Secondary outcome [28]
0
0
Arm A1 vs Arm B: Number of Participants with BOR per Investigator
Query!
Assessment method [28]
0
0
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Query!
Timepoint [28]
0
0
Up to 10 Years
Query!
Secondary outcome [29]
0
0
Arm A1 vs Arm B: Number of Participants with BOR per IRC
Query!
Assessment method [29]
0
0
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Query!
Timepoint [29]
0
0
Up to 10 Years
Query!
Secondary outcome [30]
0
0
Arm A1 vs Arm C: Number of Participants with BOR per Investigator
Query!
Assessment method [30]
0
0
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Query!
Timepoint [30]
0
0
Up to 10 Years
Query!
Secondary outcome [31]
0
0
Arm A1 vs Arm C: Number of Participants with BOR per IRC
Query!
Assessment method [31]
0
0
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Query!
Timepoint [31]
0
0
Up to 10 Years
Query!
Secondary outcome [32]
0
0
Arm A1 vs Arm A2: Number of Participants with Event-free Survival (EFS) per IRC
Query!
Assessment method [32]
0
0
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Query!
Timepoint [32]
0
0
Up to 10 Years
Query!
Secondary outcome [33]
0
0
Arm A1 vs Arm A2: Number of Participants with EFS per Investigator
Query!
Assessment method [33]
0
0
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Query!
Timepoint [33]
0
0
Up to 10 Years
Query!
Secondary outcome [34]
0
0
Arm A1 vs Arm B: Number of Participants with EFS per IRC
Query!
Assessment method [34]
0
0
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Query!
Timepoint [34]
0
0
Up to 10 Years
Query!
Secondary outcome [35]
0
0
Arm A1 vs Arm B: Number of Participants with EFS per Investigator
Query!
Assessment method [35]
0
0
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Query!
Timepoint [35]
0
0
Up to 10 Years
Query!
Secondary outcome [36]
0
0
Arm A1 vs Arm C: Number of Participants with EFS per IRC
Query!
Assessment method [36]
0
0
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Query!
Timepoint [36]
0
0
Up to 10 Years
Query!
Secondary outcome [37]
0
0
Arm A1 vs Arm C: Number of Participants with EFS per Investigator
Query!
Assessment method [37]
0
0
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Query!
Timepoint [37]
0
0
Up to 10 Years
Query!
Secondary outcome [38]
0
0
Arm A1 vs Arm A2: Duration of Response (DOR) per IRC
Query!
Assessment method [38]
0
0
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [38]
0
0
Up to 10 Years
Query!
Secondary outcome [39]
0
0
Arm A1 vs Arm A2: DOR per Investigator
Query!
Assessment method [39]
0
0
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [39]
0
0
Up to 10 Years
Query!
Secondary outcome [40]
0
0
Arm A1 vs Arm B: DOR per IRC
Query!
Assessment method [40]
0
0
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [40]
0
0
Up to 10 Years
Query!
Secondary outcome [41]
0
0
Arm A1 vs Arm B: DOR per Investigator
Query!
Assessment method [41]
0
0
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [41]
0
0
Up to 10 Years
Query!
Secondary outcome [42]
0
0
Arm A1 vs Arm C: DOR per IRC
Query!
Assessment method [42]
0
0
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [42]
0
0
Up to 10 Years
Query!
Secondary outcome [43]
0
0
Arm A1 vs Arm C: DOR per Investigator
Query!
Assessment method [43]
0
0
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [43]
0
0
Up to 10 Years
Query!
Secondary outcome [44]
0
0
Arm A1 vs Arm A2: Duration of Complete Response (DOCR) per IRC
Query!
Assessment method [44]
0
0
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [44]
0
0
Up to 10 Years
Query!
Secondary outcome [45]
0
0
Arm A1 vs Arm A2: DOCR per Investigator
Query!
Assessment method [45]
0
0
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [45]
0
0
Up to 10 Years
Query!
Secondary outcome [46]
0
0
Arm A1 vs Arm B: DOCR per IRC
Query!
Assessment method [46]
0
0
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [46]
0
0
Up to 10 Years
Query!
Secondary outcome [47]
0
0
Arm A1 vs Arm B: DOCR per Investigator
Query!
Assessment method [47]
0
0
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [47]
0
0
Up to 10 Years
Query!
Secondary outcome [48]
0
0
Arm A1 vs Arm C: DOCR per IRC
Query!
Assessment method [48]
0
0
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [48]
0
0
Up to 10 Years
Query!
Secondary outcome [49]
0
0
Arm A1 vs Arm C: DOCR per Investigator
Query!
Assessment method [49]
0
0
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [49]
0
0
Up to 10 Years
Query!
Secondary outcome [50]
0
0
Arm A1 vs Arm A2: Time to Next Anti-lymphoma Therapy (TTNT) per Investigator
Query!
Assessment method [50]
0
0
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Query!
Timepoint [50]
0
0
Up to 10 Years
Query!
Secondary outcome [51]
0
0
Arm A1 vs Arm A2: TTNT per IRC
Query!
Assessment method [51]
0
0
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Query!
Timepoint [51]
0
0
Up to 10 Years
Query!
Secondary outcome [52]
0
0
Arm A1 vs Arm A2: TTNT per Investigator
Query!
Assessment method [52]
0
0
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Query!
Timepoint [52]
0
0
Up to 10 Years
Query!
Secondary outcome [53]
0
0
Arm A1 vs Arm B: TTNT per IRC
Query!
Assessment method [53]
0
0
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Query!
Timepoint [53]
0
0
Up to 10 Years
Query!
Secondary outcome [54]
0
0
Arm A1 vs Arm B: TTNT per Investigator
Query!
Assessment method [54]
0
0
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Query!
Timepoint [54]
0
0
Up to 10 Years
Query!
Secondary outcome [55]
0
0
Arm A1 vs Arm C: TTNT per IRC
Query!
Assessment method [55]
0
0
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Query!
Timepoint [55]
0
0
Up to 10 Years
Query!
Secondary outcome [56]
0
0
Arm A1 vs Arm C: TTNT per Investigator
Query!
Assessment method [56]
0
0
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Query!
Timepoint [56]
0
0
Up to 10 Years
Query!
Secondary outcome [57]
0
0
Arm A1 vs Arm A2: Time to Progression per IRC
Query!
Assessment method [57]
0
0
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [57]
0
0
Up to 10 Years
Query!
Secondary outcome [58]
0
0
Arm A1 vs Arm A2: Time to Progression per Investigator
Query!
Assessment method [58]
0
0
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [58]
0
0
Up to 10 Years
Query!
Secondary outcome [59]
0
0
Arm A1 vs Arm B: Time to Progression per IRC
Query!
Assessment method [59]
0
0
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [59]
0
0
Up to 10 Years
Query!
Secondary outcome [60]
0
0
Arm A1 vs Arm B: Time to Progression per Investigator
Query!
Assessment method [60]
0
0
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [60]
0
0
Up to 10 Years
Query!
Secondary outcome [61]
0
0
Arm A1 vs Arm C: Time to Progression per IRC
Query!
Assessment method [61]
0
0
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Query!
Timepoint [61]
0
0
Up to 10 Years
Query!
Secondary outcome [62]
0
0
Arm A1 vs Arm C: Time to Progression per Investigator
Query!
Assessment method [62]
0
0
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Query!
Timepoint [62]
0
0
Up to 10 Years
Query!
Secondary outcome [63]
0
0
Arm A1 vs Arm A2: Number of Participants with Progression-free Survival After Subsequent Anti-Lymphoma Therapy (PFS2)
Query!
Assessment method [63]
0
0
PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Query!
Timepoint [63]
0
0
Up to 10 Years
Query!
Secondary outcome [64]
0
0
Arm A1 vs Arm B: Number of Participants with PFS2
Query!
Assessment method [64]
0
0
PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Query!
Timepoint [64]
0
0
Up to 10 Years
Query!
Secondary outcome [65]
0
0
Arm A1 vs Arm C: Number of Participants with PFS2
Query!
Assessment method [65]
0
0
PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Query!
Timepoint [65]
0
0
Up to 10 Years
Query!
Secondary outcome [66]
0
0
Arm A1 vs Arm A2: Change in Tolerability as Measured by Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Query!
Assessment method [66]
0
0
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Query!
Timepoint [66]
0
0
Up to 10 Years
Query!
Secondary outcome [67]
0
0
Arm A1 vs Arm B: Change in Tolerability as Measured by PRO-CTCAE
Query!
Assessment method [67]
0
0
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Query!
Timepoint [67]
0
0
Up to 10 Years
Query!
Secondary outcome [68]
0
0
Arm A1 vs Arm C: Change in Tolerability as Measured by PRO-CTCAE
Query!
Assessment method [68]
0
0
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Query!
Timepoint [68]
0
0
Up to 10 Years
Query!
Secondary outcome [69]
0
0
Arm A1 vs Arm A2: Change in Tolerability as Measured by The Functional Assessment of Cancer Therapy - General (FACT-G) Item GP5
Query!
Assessment method [69]
0
0
The functional assessment of cancer therapy singly item - GP5 (FACT-GP5) is a single question asking if participant is bothered by side effects of treatment.
Query!
Timepoint [69]
0
0
Up to 10 Years
Query!
Secondary outcome [70]
0
0
Arm A1 vs Arm B: Change in Tolerability as Measured by FACT-G Item GP5
Query!
Assessment method [70]
0
0
The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.
Query!
Timepoint [70]
0
0
Up to 10 Years
Query!
Secondary outcome [71]
0
0
Arm A1 vs Arm C: Change in Tolerability as Measured by FACT-GG Item GP5
Query!
Assessment method [71]
0
0
The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.
Query!
Timepoint [71]
0
0
Up to 10 Years
Query!
Secondary outcome [72]
0
0
Arm A1 vs Arm A2: Change in Symptoms as Measured by The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)
Query!
Assessment method [72]
0
0
The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [72]
0
0
Up to 10 Years
Query!
Secondary outcome [73]
0
0
Arm A1 vs Arm B: Change in Symptoms as Measured by FACT-Lym
Query!
Assessment method [73]
0
0
The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [73]
0
0
Up to 10 Years
Query!
Secondary outcome [74]
0
0
Arm A1 vs Arm C: Change in Symptoms as Measured by FACT-Lym
Query!
Assessment method [74]
0
0
The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [74]
0
0
Up to 10 Years
Query!
Secondary outcome [75]
0
0
Arm A1 vs Arm A2: Change in Quality of Life (QoL) as Measured by FACT-Lym
Query!
Assessment method [75]
0
0
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [75]
0
0
Up to 10 Years
Query!
Secondary outcome [76]
0
0
Arm A1 vs Arm B: Change in QoL as Measured by FACT-Lym
Query!
Assessment method [76]
0
0
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [76]
0
0
Up to 10 Years
Query!
Secondary outcome [77]
0
0
Arm A1 vs Arm C: Change in QoL as Measured by FACT-Lym
Query!
Assessment method [77]
0
0
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [77]
0
0
Up to 10 Years
Query!
Secondary outcome [78]
0
0
Arm A1 vs Arm A2: Time-to-first PRO deterioration (TTD) in well-being using the lymphoma subscale (LymS) of FACT-Lym
Query!
Assessment method [78]
0
0
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [78]
0
0
Up to 10 Years
Query!
Secondary outcome [79]
0
0
Arm A1 vs Arm B: TTD in well-being using LymS of FACT-Lym
Query!
Assessment method [79]
0
0
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [79]
0
0
Up to 10 Years
Query!
Secondary outcome [80]
0
0
Arm A1 vs Arm C: TTD in well-being using LymS of FACT-Lym
Query!
Assessment method [80]
0
0
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Query!
Timepoint [80]
0
0
Up to 10 Years
Query!
Secondary outcome [81]
0
0
Arm A1 vs Arm A2: Change in QoL as Measured by 5-Level European Quality of Life (EuroQol)-5-dimension [EQ-5D-5L]
Query!
Assessment method [81]
0
0
The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.
Query!
Timepoint [81]
0
0
Up to 10 Years
Query!
Secondary outcome [82]
0
0
Arm A1 vs Arm B: Change in QoL as Measured by EQ-5D-5L
Query!
Assessment method [82]
0
0
The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.
Query!
Timepoint [82]
0
0
Up to 10 Years
Query!
Secondary outcome [83]
0
0
Arm A1 vs Arm C: Change in QoL as Measured by EQ-5D-5L
Query!
Assessment method [83]
0
0
The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.
Query!
Timepoint [83]
0
0
Up to 10 Years
Query!
Secondary outcome [84]
0
0
Arm A1 vs Arm A2: TTD in PF using the QLQ-C30 Physical Functioning Scale
Query!
Assessment method [84]
0
0
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Query!
Timepoint [84]
0
0
Up to 10 Years
Query!
Secondary outcome [85]
0
0
Arm A1 vs Arm B: TTD in PF using the QLQ-C30 Physical Functioning Scale
Query!
Assessment method [85]
0
0
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Query!
Timepoint [85]
0
0
Up to 10 Years
Query!
Secondary outcome [86]
0
0
Arm A1 vs Arm C: TTD in PF using the QLQ-C30 Physical Functioning Scale
Query!
Assessment method [86]
0
0
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Query!
Timepoint [86]
0
0
Up to 10 Years
Query!
Secondary outcome [87]
0
0
Arm A1 vs Arm A2: Change from baseline in the remaining items and domains of the EORTC QLQ-C30
Query!
Assessment method [87]
0
0
The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.
Query!
Timepoint [87]
0
0
Up to 10 Years
Query!
Secondary outcome [88]
0
0
Arm A1 vs Arm B: Change from baseline in the remaining items and domains of the EORTC QLQ-C30
Query!
Assessment method [88]
0
0
The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.
Query!
Timepoint [88]
0
0
Up to 10 Years
Query!
Secondary outcome [89]
0
0
Arm A1 vs Arm C: Change from baseline in the remaining items and domains of the EORTC QLQ-C30
Query!
Assessment method [89]
0
0
The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.
Query!
Timepoint [89]
0
0
Up to 10 Years
Query!
Secondary outcome [90]
0
0
Arm A1 vs Arm A2: Change in Patient Global Impression of Change (PGIC) for General Lymphoma Symptoms
Query!
Assessment method [90]
0
0
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Query!
Timepoint [90]
0
0
Up to 10 Years
Query!
Secondary outcome [91]
0
0
Arm A1 vs Arm C: Change in PGIC for General Lymphoma Symptoms
Query!
Assessment method [91]
0
0
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Query!
Timepoint [91]
0
0
Up to 10 Years
Query!
Secondary outcome [92]
0
0
Arm A1 vs Arm A2: Change in Patient Global Impression of Severity (PGIS) for General Lymphoma Symptoms
Query!
Assessment method [92]
0
0
The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Query!
Timepoint [92]
0
0
Up to 10 Years
Query!
Secondary outcome [93]
0
0
Arm A1 vs Arm B: Change in PGIS for General Lymphoma Symptoms
Query!
Assessment method [93]
0
0
The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Query!
Timepoint [93]
0
0
Up to 10 Years
Query!
Secondary outcome [94]
0
0
Arm A1 vs Arm C: Change in PGIS for General Lymphoma Symptoms
Query!
Assessment method [94]
0
0
The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Query!
Timepoint [94]
0
0
Up to 10 Years
Query!
Eligibility
Key inclusion criteria
* Diagnosis of follicular lymphoma (FL).
* Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
* Are willing and able to comply with procedures required in the protocol.
* Must have stage, III, IV or II with bulky disease >= 7cm).
* Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
* Has one or more target lesions:
* A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
* >=1 measurable nodal lesion (long axis >1.5cm) or >=1 measurable extra-nodal lesion (long axis >1.0 cm) on CT scan or MRI
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
* Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: [Arm B] at the discretion of the Investigator, and rituximab and lenalidomide (R2) [Arm C].
* Have laboratory values meeting the criteria in the protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Had major surgery within 4 weeks prior to randomization.
* Have active cytomegalovirus (CMV) disease.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/02/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/11/2037
Query!
Actual
Query!
Sample size
Target
1095
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital /ID# 259320 - Camperdown
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital /ID# 259321 - Liverpool
Query!
Recruitment hospital [3]
0
0
Peter MacCallum Cancer Center /ID# 260431 - Melbourne
Query!
Recruitment hospital [4]
0
0
Westmead Hospital /ID# 261465 - Westmead
Query!
Recruitment hospital [5]
0
0
Townsville University Hospital /ID# 259323 - Douglas
Query!
Recruitment hospital [6]
0
0
Royal Brisbane and Women's Hospital /ID# 259326 - Herston
Query!
Recruitment hospital [7]
0
0
Princess Alexandra Hospital /ID# 259329 - Woolloongabba
Query!
Recruitment hospital [8]
0
0
Peninsula Private Hospital /ID# 259325 - Frankston
Query!
Recruitment hospital [9]
0
0
Fiona Stanley Hospital /ID# 259324 - Murdoch
Query!
Recruitment hospital [10]
0
0
Royal Perth Hospital /ID# 259319 - Perth
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [5]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [6]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [7]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [8]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [9]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [10]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Delaware
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maine
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Montana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Mexico
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oregon
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Washington
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Antwerpen
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Bruxelles-Capitale
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Oost-Vlaanderen
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Vlaams-Brabant
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
West-Vlaanderen
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Liege
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Pleven
Query!
Country [32]
0
0
Bulgaria
Query!
State/province [32]
0
0
Sofia
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Ontario
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Quebec
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Beijing
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Fujian
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Guangdong
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Guangxi
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Henan
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Hubei
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Hunan
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Jiangsu
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Jiangxi
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Liaoning
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Shandong
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Shanghai
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Sichuan
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Tianjin
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Xinjiang
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Yunnan
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Zhejiang
Query!
Country [52]
0
0
Croatia
Query!
State/province [52]
0
0
Grad Zagreb
Query!
Country [53]
0
0
Croatia
Query!
State/province [53]
0
0
Primorsko-goranska Zupanija
Query!
Country [54]
0
0
Croatia
Query!
State/province [54]
0
0
Splitsko-dalmatinska Zupanija
Query!
Country [55]
0
0
Croatia
Query!
State/province [55]
0
0
Zadar
Query!
Country [56]
0
0
Czechia
Query!
State/province [56]
0
0
Hradec Kralove
Query!
Country [57]
0
0
Czechia
Query!
State/province [57]
0
0
Praha
Query!
Country [58]
0
0
Denmark
Query!
State/province [58]
0
0
Midtjylland
Query!
Country [59]
0
0
Denmark
Query!
State/province [59]
0
0
Sjælland
Query!
Country [60]
0
0
Denmark
Query!
State/province [60]
0
0
Syddanmark
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Loire-Atlantique
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Provence-Alpes-Cote-d Azur
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Rhone
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Sarthe
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Caen
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Libourne
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Paris
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Strasbourg
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Baden-Wuerttemberg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Hessen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Nordrhein-Westfalen
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Rheinland-Pfalz
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Magdeburg
Query!
Country [74]
0
0
Greece
Query!
State/province [74]
0
0
Achaia
Query!
Country [75]
0
0
Greece
Query!
State/province [75]
0
0
Attiki
Query!
Country [76]
0
0
Greece
Query!
State/province [76]
0
0
Alexandroupolis
Query!
Country [77]
0
0
Greece
Query!
State/province [77]
0
0
Athens
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Gyor-Moson-Sopron
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Tolna
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Vas
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Budapest
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
HaDarom
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Haifa
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
HaMerkaz
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Tel-Aviv
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Yerushalayim
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Petah Tikva
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Torino
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Bologna
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Palermo
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Reggio Emilia
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Roma
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Aichi
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Ehime
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Fukui
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Fukuoka
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Fukushima
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Hiroshima
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Hokkaido
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Hyogo
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Ibaraki
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Kanagawa
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Okayama
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Osaka
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Tokyo
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Yamaguchi
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Yamanashi
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Aomori
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Chiba
Query!
Country [110]
0
0
Korea, Republic of
Query!
State/province [110]
0
0
Gyeonggido
Query!
Country [111]
0
0
Korea, Republic of
Query!
State/province [111]
0
0
Seoul Teugbyeolsi
Query!
Country [112]
0
0
Netherlands
Query!
State/province [112]
0
0
Noord-Brabant
Query!
Country [113]
0
0
Netherlands
Query!
State/province [113]
0
0
Noord-Holland
Query!
Country [114]
0
0
Netherlands
Query!
State/province [114]
0
0
Utrecht
Query!
Country [115]
0
0
Netherlands
Query!
State/province [115]
0
0
Zuid-Holland
Query!
Country [116]
0
0
Netherlands
Query!
State/province [116]
0
0
Arnhem
Query!
Country [117]
0
0
Netherlands
Query!
State/province [117]
0
0
Groningen
Query!
Country [118]
0
0
New Zealand
Query!
State/province [118]
0
0
Auckland
Query!
Country [119]
0
0
Poland
Query!
State/province [119]
0
0
Lodzkie
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Malopolskie
Query!
Country [121]
0
0
Poland
Query!
State/province [121]
0
0
Mazowieckie
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Swietokrzyskie
Query!
Country [123]
0
0
Portugal
Query!
State/province [123]
0
0
Lisboa
Query!
Country [124]
0
0
Portugal
Query!
State/province [124]
0
0
Porto
Query!
Country [125]
0
0
Puerto Rico
Query!
State/province [125]
0
0
Rio Piedras
Query!
Country [126]
0
0
Puerto Rico
Query!
State/province [126]
0
0
San Juan
Query!
Country [127]
0
0
Romania
Query!
State/province [127]
0
0
Bucuresti
Query!
Country [128]
0
0
Romania
Query!
State/province [128]
0
0
Cluj
Query!
Country [129]
0
0
Romania
Query!
State/province [129]
0
0
Iasi
Query!
Country [130]
0
0
Romania
Query!
State/province [130]
0
0
Bucharest
Query!
Country [131]
0
0
Serbia
Query!
State/province [131]
0
0
Beograd
Query!
Country [132]
0
0
Serbia
Query!
State/province [132]
0
0
Sumadijski Okrug
Query!
Country [133]
0
0
Serbia
Query!
State/province [133]
0
0
Vojvodina
Query!
Country [134]
0
0
Serbia
Query!
State/province [134]
0
0
Novi Sad
Query!
Country [135]
0
0
Slovakia
Query!
State/province [135]
0
0
Bratislavsky Kraj
Query!
Country [136]
0
0
Slovakia
Query!
State/province [136]
0
0
Zilinsky Kraj
Query!
Country [137]
0
0
South Africa
Query!
State/province [137]
0
0
Gauteng
Query!
Country [138]
0
0
South Africa
Query!
State/province [138]
0
0
Western Cape
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Barcelona
Query!
Country [140]
0
0
Spain
Query!
State/province [140]
0
0
Cantabria
Query!
Country [141]
0
0
Spain
Query!
State/province [141]
0
0
Navarra
Query!
Country [142]
0
0
Spain
Query!
State/province [142]
0
0
Caceres
Query!
Country [143]
0
0
Spain
Query!
State/province [143]
0
0
Madrid
Query!
Country [144]
0
0
Spain
Query!
State/province [144]
0
0
Salamanca
Query!
Country [145]
0
0
Sweden
Query!
State/province [145]
0
0
Vastra Gotalands Lan
Query!
Country [146]
0
0
Taiwan
Query!
State/province [146]
0
0
Taipei
Query!
Country [147]
0
0
Taiwan
Query!
State/province [147]
0
0
Taichung
Query!
Country [148]
0
0
Taiwan
Query!
State/province [148]
0
0
Tainan
Query!
Country [149]
0
0
Turkey
Query!
State/province [149]
0
0
Istanbul
Query!
Country [150]
0
0
Turkey
Query!
State/province [150]
0
0
Izmir
Query!
Country [151]
0
0
Turkey
Query!
State/province [151]
0
0
Kocaeli
Query!
Country [152]
0
0
Turkey
Query!
State/province [152]
0
0
Samsun
Query!
Country [153]
0
0
Turkey
Query!
State/province [153]
0
0
Sisli
Query!
Country [154]
0
0
United Kingdom
Query!
State/province [154]
0
0
Devon
Query!
Country [155]
0
0
United Kingdom
Query!
State/province [155]
0
0
England
Query!
Country [156]
0
0
United Kingdom
Query!
State/province [156]
0
0
Hampshire
Query!
Country [157]
0
0
United Kingdom
Query!
State/province [157]
0
0
West Yorkshire
Query!
Country [158]
0
0
United Kingdom
Query!
State/province [158]
0
0
Manchester
Query!
Country [159]
0
0
United Kingdom
Query!
State/province [159]
0
0
Newcastle upon Tyne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Genmab
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
AbbVie
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world. Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \[G-CHOP\]/ R-CHOP or G and IV infusion of bendamustine (Benda) \[G-Benda\]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06191744
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
ABBVIE CALL CENTER
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-663-3742
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Query!
Available to whom?
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/ourmember/abbvie/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06191744
Download to PDF